ABOUT MILTENYI BIOINDUSTRY
Miltenyi Bioindustry supports all efforts, from pre-clinical to commercial scale, as a full-service provider for the development and manufacturing of lentiviral vectors (LVVs) and cell and gene therapy (CGT) products. As a globally active CDMO (Contract Development and Manufacturing Organization) with 25 years of extensive know-how, we are helping to shape this rapidly growing arena. We leverage the latest technology platforms to make your vision of commercial-scale manufacturing a reality. We are a division of Miltenyi Biotec, a pioneering innovator and provider of cell processing and analytical platforms, LVVs, and ancillary materials in this field.
FEATURED CONTENT
-
![GettyImages-2139576234-partner-team-collaborate-collaboration-meet]( "How Collaborative Preparation Drives Optimal Tech Transfer Execution")
Tech transfer missteps risk higher costs and lower product quality. Success hinges on a clear sponsor strategy and working with an experienced, collaborative CDMO.
-
![GettyImages-2181934436-laboratory-analysis-scientists-technology-computer]( "Streamline Analytical Tech Transfer Through Analytical Target Profile")
Analytics debt in CGT can derail timelines and budgets. Learn how early ATP planning and cross-functional alignment can eliminate costly setbacks and accelerate IND approvals.
-
![GettyImages-1583149311 biomanufacturing, automation, robotics]( "Enhancing Preclinical Cell Therapy Development")
Automation in cell therapy development boosts reproducibility, reduces error, and enhances yield. Learn how it’s reshaping preclinical workflows and accelerating clinical trial readiness.
-
![GettyImages-1590452153-assay-well-plate-microcscope-image]( "Streamline Analytical Tech Transfer Through ATP Diligence And Standardization")
Early-stage assays not guided by a detailed analytical target profile often reach QC with missing controls, undefined sample-suitability limits, and protocols that need a GMP overhaul.
-
![Gaithersburg_Lentiviral_Vector_section_CleanRoom_7196_RGB_001]( "The Power Of A Platform Process For Lentiviral Vectors")
A robust platform process can help ensure therapeutic efficacy and supply chain security for LVV-based products, as well as support aggressive development and commercialization timelines.
-
![GettyImages-2163607311-scientist-assay-cell-culture-laboratory-gloves]( "Enhancing Cell And Gene Therapy: The LVV Platform Advantage")
Many drug development platforms focus solely on cost reduction or improved process efficiency, offering few, if any, solutions to bolster biological performance.
CONTACT INFORMATION
Miltenyi Bioindustry
6125 Cornerstone Court East
San Diego, CA 92121
UNITED STATES
